Your watchlist
2 of 10 picked (the Pro limit).
Like it? Pro watches these for you and emails a digest daily or weekly.
Get Pro · $49/monthOr the free weekly briefWeek of Oct 26 · 1 item
Lifeward reports changes involving its directors or officers (Form 8-K, Item 5.02)
“On October 26, 2026, the Board of Directors (the “Board”) of Lifeward Ltd. (the “Company”) appointed Ronen Tsimerman, age 56, as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective …”
You follow Lifeward · Regulatory filing
Week of Sep 28 · 3 items
Lifeward reports changes involving its directors or officers (Form 8-K, Item 5.02)
“As previously reported in Current Reports on Form 8-K filed with the Securities and Exchange Commission on August 31, 2026 and October 1, 2026, Lifeward Ltd. (the “Company”) appointed Rami Aviram as its Chief Financial Officer, principal fi…”
You follow Lifeward · Regulatory filing
Lifeward reports changes involving its directors or officers (Form 8-K, Item 5.02)
“As previously disclosed in the Current Report on Form 8-K filed by Lifeward Ltd. (the “Company”) with the Securities and Exchange Commission on August 31, 2026, Almog Adar’s departure as the Company’s Chief Financial Officer, principal fina…”
You follow Lifeward · Regulatory filing
Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in Its Transition Toward Commercial Revenue Generation
“HOUSTON – October 1, 2026 – Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has signed a definitive intern…”
You follow Nexalin Technology · Company-reported
Week of Sep 21 · 1 item
Nexalin Technology reports a notice about its stock exchange listing (Form 8-K, Item 3.01)
“As previously reported, on September 1, 2026, Nexalin Technology, Inc. (the “Company”) presented its plan of compliance to the Hearings Panel (the “Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) and requested continued listing on Nasdaq …”
You follow Nexalin Technology · Regulatory filing
Week of Sep 14 · 1 item
Lifeward reports a shareholder director nomination deadline (Form 8-K, Item 5.08)
“The Board of Directors (the “Board”) of Lifeward Ltd. (the “Company”) has set October 30, 2026 as the date for the Company’s 2026 Annual and Extraordinary General Meeting of Shareholders (the “Annual Meeting”).”
You follow Lifeward · Regulatory filing
Week of Aug 31 · 1 item
Lifeward reports changes involving its directors or officers (Form 8-K, Item 5.02)
“Effective August 31, 2026, Mr. Mark Grant will depart from his positions as the President and Chief Executive Officer of Lifeward Ltd. (the “Company”) and as a member of the Company’s Board of Directors (the “Board”), following the Company’…”
You follow Lifeward · Regulatory filing
Week of Aug 24 · 2 items
Nexalin Technology reports changes involving its directors or officers (Form 8-K, Item 5.02)
“On August 28, 2026, Carolyn Shelton departed from her role as Senior Vice President of Quality, Regulatory, and Clinical Affairs of Nexalin Technology, Inc. (the “Company”).”
You follow Nexalin Technology · Regulatory filing
Nexalin Technology Announces Reverse Stock Split
“HOUSTON – August 27, 2026 – Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), announces that its board of directors has approved a 1-for-30 reverse stock split of the Company’s common stock, to ensure continued compliance…”
You follow Nexalin Technology · Company-reported
Week of Aug 17 · 2 items
Nexalin Technology reports entry into a material definitive agreement (Form 8-K, Item 1.01)
“On August 21, 2026, Nexalin Technology, Inc. (the “Company”) entered into a Note Purchase Agreement (the “Note Purchase Agreement”) with an institutional investor (the “Investor”), pursuant to which the Investor purchased from the Company a…”
You follow Nexalin Technology · Regulatory filing
Nexalin Technology reports entry into a material definitive agreement (Form 8-K, Item 1.01)
“On August 19, 2026, Nexalin Technology, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a single institutional investor (the “Investor”), pursuant to which the Company agreed to issue and se…”
You follow Nexalin Technology · Regulatory filing
Week of Aug 10 · 4 items
Lifeward reports changes involving its directors or officers (Form 8-K, Item 5.02)
“Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer.”
You follow Lifeward · Regulatory filing
Nexalin Technology reports a notice about its stock exchange listing (Form 8-K, Item 3.01)
“On August 14, 2026, Nexalin Technology, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the stockholder…”
You follow Nexalin Technology · Regulatory filing
Nexalin Technology reports results of a shareholder vote (Form 8-K, Item 5.07)
“The annual meeting (the “Annual Meeting”) of the stockholders of Nexalin Technology, Inc. (the “Company”) was convened at 10:00 a.m. Eastern time on August 11, 2026. Of the 22,011,302 shares of the Company’s common stock, par value $0.001 p…”
You follow Nexalin Technology · Regulatory filing
Lifeward Reports Strong Second Quarter 2026 Financial Results as Commercial Execution Drives Growth
“HUDSON, MA, and YOKNEAM ILLIT, Israel, August 14, 2026 – Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedica…”
You follow Lifeward · Company-reported
5 of the last 13 weeks had nothing for this watchlist; those digests would have said so plainly.